News & Articles

FEATURED ARTICLE

MASP2 Antibody Successful in Phase III Clinical Trial

On December 19, 2024, Omeros announced that its pivotal Phase 3 clinical trial of the MASP2 antibody Narsoplimab (OMS721) in the treatment of TA-TMA (Transplant-Associated Thrombotic Microangiopathy) met its primary endpoint of overall survival (OS), with a 3-fold reduction in mortality risk [1]. Omeros stock surged 37% after the press release...

Read more

Browse articles by topic:

Rethinking Refolding: The Case for Mammalian-Expressed Single-Chain Trimer MHCs

Rethinking Refolding: The Case for Mammalian-Expressed Single-Chain Trimer MHCs

September 18, 2024

5 min read

For years, recombinant major histocompatibility complexes (MHCs) have been expressed in bacterial systems with in vitro refolding. While this preserves...

Read more →
Neoantigen-Based Immunotherapy: Unveiling Disease-Specific Targets

Neoantigen-Based Immunotherapy: Unveiling Disease-Specific Targets

August 20, 2024

3 min read

Introducing Neoantigen-Based Immunotherapy Neoantigen-based immunotherapy is revolutionizing cancer treatment by focusing on neoantigens—unique proteins formed by mutations in cancer cells....

Read more →
Webinar: Transforming Tumor Research: Engineering MHCs as Versatile Reagents

Webinar: Transforming Tumor Research: Engineering MHCs as Versatile Reagents

December 20, 2023

Speaker Dr. Manhee Suh, Co-founder & CTO, KACTUS What's Inside When dealing with solid tumors lacking specific biomarkers, the effectiveness...

Read more →
Transforming Tumor Research: Engineering MHCs as Versatile Reagents

Transforming Tumor Research: Engineering MHCs as Versatile Reagents

September 7, 2023

1 min read

ManHee Suh's Talk @ CAR-TCR Summit We are delighted to share with you our experience at the 8th CAR-TCR Summit...

Read more →
Cell and Antibody Therapies Targeting HLA-G

Cell and Antibody Therapies Targeting HLA-G

February 14, 2023

3 min read

On December 19, 2022, the FDA approved the Phase I/IIa clinical trial application of IVS-3001, an anti-HLA-G Chimeric Antigen Receptor-T...

Read more →
TCR Therapy Targeting MAGE-A4

TCR Therapy Targeting MAGE-A4

January 2, 2023

1 min read

Recently at the 2022 CTOS Conference, Adaptimmune announced the SPEARHEAD-1 clinical trial data of its T cell receptor-engineered T cell...

Read more →

Have questions? Get in touch!

support@kactusbio.us

Contact Us